Skip to main content
Erschienen in: Psychiatric Quarterly 2/2015

01.06.2015 | Original Paper

Antipsychotic Medication-Induced Dysphoria: Its Meaning, Association with Typical vs. Atypical Medications and Impact on Adherence

verfasst von: Hanjing Emily Wu, Olaoluwa O. Okusaga

Erschienen in: Psychiatric Quarterly | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Antipsychotic medication-induced dysphoria is a relatively under-recognized and understudied effect of antipsychotic medication. Although the term is encountered in clinical practice and in the literature, there is no consensus regarding its exact meaning. This article is a narrative review of the literature on antipsychotic medication and dysphoria based on a pubmed database search. We found that antipsychotic medication-induced dysphoria is a term used to describe a negative and unpleasant affective state which seems to be more often associated with high potency first-generation antipsychotics and could potentially lead to medication non-adherence. Though it is plausible to expect antipsychotic medication-induced dysphoria to be related to extrapyramidal symptoms, most especially akathisia, the nature of the association remains unspecified. Furthermore, there is some evidence that dopamine blockade maybe involved in the pathogenesis of antipsychotic medication-induced dysphoria. However, the limited methods of the currently available studies make it impossible to conclusively address the question of which class of antipsychotic (first- or second-generation) has a higher prevalence and severity of the syndrome.
Literatur
1.
Zurück zum Zitat King C, Voruganti LN: What’s in a name? The evolution of the nomenclature of antipsychotic drugs. Journal of Psychiatry and Neuroscience 27:168–175, 2002.PubMedCentralPubMed King C, Voruganti LN: What’s in a name? The evolution of the nomenclature of antipsychotic drugs. Journal of Psychiatry and Neuroscience 27:168–175, 2002.PubMedCentralPubMed
2.
Zurück zum Zitat Harrison PJ: The neuropathological effects of antipsychotic drugs. Schizophrenia Research 40:87–99, 1999.PubMedCrossRef Harrison PJ: The neuropathological effects of antipsychotic drugs. Schizophrenia Research 40:87–99, 1999.PubMedCrossRef
3.
Zurück zum Zitat Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51–68, 1999.PubMedCrossRef Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51–68, 1999.PubMedCrossRef
4.
Zurück zum Zitat King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 167:480–482, 1995.PubMedCrossRef King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 167:480–482, 1995.PubMedCrossRef
5.
Zurück zum Zitat Lynch G, Green JF, King DJ: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 169:524, 1996.PubMedCrossRef Lynch G, Green JF, King DJ: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 169:524, 1996.PubMedCrossRef
6.
Zurück zum Zitat Noordsy DL, Drake RE, Teague GB, Osher FC, Hurlbut SC, Beaudett MS, et al.: Subjective experiences related to alcohol use among schizophrenics. The Journal of nervous and mental disease 179:410–414, 1991.PubMedCrossRef Noordsy DL, Drake RE, Teague GB, Osher FC, Hurlbut SC, Beaudett MS, et al.: Subjective experiences related to alcohol use among schizophrenics. The Journal of nervous and mental disease 179:410–414, 1991.PubMedCrossRef
7.
Zurück zum Zitat Mueser KT, Drake RE, Wallach MA: Dual diagnosis: a review of etiological theories. Addictive Behaviors 23:717–734, 1998.PubMedCrossRef Mueser KT, Drake RE, Wallach MA: Dual diagnosis: a review of etiological theories. Addictive Behaviors 23:717–734, 1998.PubMedCrossRef
8.
Zurück zum Zitat Voruganti LN, Heslegrave RJ, Awad AG: Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. The Journal of Nervous and Mental Disease 185:463–465, 1997.PubMedCrossRef Voruganti LN, Heslegrave RJ, Awad AG: Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. The Journal of Nervous and Mental Disease 185:463–465, 1997.PubMedCrossRef
9.
Zurück zum Zitat Awad AG, Voruganti LN: Quality of life and new antipsychotics in schizophrenia. Are patients better off? International Journal of Social Psychiatry 45:268–275, 1999.PubMedCrossRef Awad AG, Voruganti LN: Quality of life and new antipsychotics in schizophrenia. Are patients better off? International Journal of Social Psychiatry 45:268–275, 1999.PubMedCrossRef
10.
Zurück zum Zitat Singh MM, Smith JM: Kinetics and dynamics of response to haloperidol in acute schizophrenia–A longitudinal study of the therapeutic process. Comprehensive Psychiatry 14:393–414, 1973.PubMedCrossRef Singh MM, Smith JM: Kinetics and dynamics of response to haloperidol in acute schizophrenia–A longitudinal study of the therapeutic process. Comprehensive Psychiatry 14:393–414, 1973.PubMedCrossRef
11.
Zurück zum Zitat Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American journal of psychiatry 136:1576, 1979.CrossRef Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American journal of psychiatry 136:1576, 1979.CrossRef
12.
Zurück zum Zitat Bruun RD: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. The American Journal of Psychiatry 145:621–624, 1988.PubMedCrossRef Bruun RD: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. The American Journal of Psychiatry 145:621–624, 1988.PubMedCrossRef
13.
Zurück zum Zitat Weiden PJ, John Mann J, Dixon L, Haas G, Dechillo N, Frances AJ: Is neuroleptic dysphoria a healthy response? Comprehensive Psychiatry 30:546–552, 1989.PubMedCrossRef Weiden PJ, John Mann J, Dixon L, Haas G, Dechillo N, Frances AJ: Is neuroleptic dysphoria a healthy response? Comprehensive Psychiatry 30:546–552, 1989.PubMedCrossRef
14.
Zurück zum Zitat Newcomer JW, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG: Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. The British Journal of Psychiatry 164:834–838, 1994.PubMedCrossRef Newcomer JW, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG: Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. The British Journal of Psychiatry 164:834–838, 1994.PubMedCrossRef
15.
Zurück zum Zitat Awad AG, Voruganti L: New antipsychotics, compliance, quality of life, and subjective tolerability–are patients better off? Canadian Journal of Psychiatry 49:297–302, 2004.PubMed Awad AG, Voruganti L: New antipsychotics, compliance, quality of life, and subjective tolerability–are patients better off? Canadian Journal of Psychiatry 49:297–302, 2004.PubMed
16.
Zurück zum Zitat Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al: Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25:642–650, 2001.PubMedCrossRef Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al: Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25:642–650, 2001.PubMedCrossRef
17.
Zurück zum Zitat Voruganti L, Awad AG: Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatrica Scandinavica 111:22–28, 2005.CrossRef Voruganti L, Awad AG: Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatrica Scandinavica 111:22–28, 2005.CrossRef
18.
Zurück zum Zitat Voruganti L, Awad AG: Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171:121–132, 2004.CrossRef Voruganti L, Awad AG: Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171:121–132, 2004.CrossRef
19.
Zurück zum Zitat Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American Journal of Psychiatry 136:1216–1217, 1979.PubMedCrossRef Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American Journal of Psychiatry 136:1216–1217, 1979.PubMedCrossRef
20.
Zurück zum Zitat Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43:135–145, 2000.PubMedCrossRef Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43:135–145, 2000.PubMedCrossRef
21.
Zurück zum Zitat Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al.: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Research 57:201–208, 2002.PubMedCrossRef Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al.: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Research 57:201–208, 2002.PubMedCrossRef
22.
Zurück zum Zitat Cook PE, Goldberg JO, and Van Lieshout RJ: Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Canadian Journal of Psychiatry 47:870–874, 2002.PubMed Cook PE, Goldberg JO, and Van Lieshout RJ: Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Canadian Journal of Psychiatry 47:870–874, 2002.PubMed
23.
Zurück zum Zitat Naber D, Karow A, Lambert M: Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica. Supplementum 111:29–34, 2005.CrossRef Naber D, Karow A, Lambert M: Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica. Supplementum 111:29–34, 2005.CrossRef
24.
Zurück zum Zitat Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al.: Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50:79–88, 2001.PubMedCrossRef Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al.: Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50:79–88, 2001.PubMedCrossRef
25.
Zurück zum Zitat Harvey PD, Rabinowitz J, Eerdeken S, Davidson M: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. The American Journal of Psychiatry 162:1888–1895, 2005.PubMedCrossRef Harvey PD, Rabinowitz J, Eerdeken S, Davidson M: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. The American Journal of Psychiatry 162:1888–1895, 2005.PubMedCrossRef
26.
Zurück zum Zitat Marder SR: Lessons from each drug trial. The American Journal of Psychiatry 164:375–376, 2007.PubMedCrossRef Marder SR: Lessons from each drug trial. The American Journal of Psychiatry 164:375–376, 2007.PubMedCrossRef
27.
Zurück zum Zitat Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatrica Scandinavica 111:81–83, 2005.PubMedCrossRef Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatrica Scandinavica 111:81–83, 2005.PubMedCrossRef
28.
Zurück zum Zitat Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Larsen TK et al.: Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early Intervention in Psychiatry 3:58–65, 2009.PubMedCrossRef Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Larsen TK et al.: Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early Intervention in Psychiatry 3:58–65, 2009.PubMedCrossRef
29.
Zurück zum Zitat Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C et al.: Maintenance treatment of schizophrenia with risperidone or haloperidol: 2 year outcomes. American Journal of Psychiatry 160:1405–1412, 2003.PubMedCrossRef Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C et al.: Maintenance treatment of schizophrenia with risperidone or haloperidol: 2 year outcomes. American Journal of Psychiatry 160:1405–1412, 2003.PubMedCrossRef
30.
Zurück zum Zitat Awad A, Hogan T: Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica 89:27–32, 1994.CrossRef Awad A, Hogan T: Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica 89:27–32, 1994.CrossRef
31.
Zurück zum Zitat Van Putten T, May PR, Marder SR, Wittmann LA: Subjective response to antipsychotic drugs. Archives of General Psychiatry 38:187–190, 1981.PubMedCrossRef Van Putten T, May PR, Marder SR, Wittmann LA: Subjective response to antipsychotic drugs. Archives of General Psychiatry 38:187–190, 1981.PubMedCrossRef
32.
Zurück zum Zitat Van Putten T, May R: Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Archives of General Psychiatry 35:477–480, 1978.PubMedCrossRef Van Putten T, May R: Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Archives of General Psychiatry 35:477–480, 1978.PubMedCrossRef
33.
Zurück zum Zitat Hogan T, Awad A: Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychological Medicine 22:347–352, 1992.PubMedCrossRef Hogan T, Awad A: Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychological Medicine 22:347–352, 1992.PubMedCrossRef
34.
Zurück zum Zitat Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J: Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8, 2006.PubMedCentralPubMedCrossRef Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J: Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8, 2006.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Koob GF, Le Moal M: Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58, 1997.PubMedCrossRef Koob GF, Le Moal M: Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58, 1997.PubMedCrossRef
36.
Zurück zum Zitat Fibiger HC: Neurobiology of depression: focus on dopamine. Advances in Biochemical Psychopharmacology 49:1–17, 1995.PubMed Fibiger HC: Neurobiology of depression: focus on dopamine. Advances in Biochemical Psychopharmacology 49:1–17, 1995.PubMed
37.
Zurück zum Zitat Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience 18:463–495, 1995.PubMedCrossRef Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience 18:463–495, 1995.PubMedCrossRef
38.
Zurück zum Zitat Wise RA: Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319–340, 1996.PubMedCrossRef Wise RA: Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319–340, 1996.PubMedCrossRef
39.
Zurück zum Zitat Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al.: Subjective effects of AMPT induced dopamine depletion in schizophrenia; the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology 25:642–650, 2001.PubMedCrossRef Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al.: Subjective effects of AMPT induced dopamine depletion in schizophrenia; the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology 25:642–650, 2001.PubMedCrossRef
Metadaten
Titel
Antipsychotic Medication-Induced Dysphoria: Its Meaning, Association with Typical vs. Atypical Medications and Impact on Adherence
verfasst von
Hanjing Emily Wu
Olaoluwa O. Okusaga
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 2/2015
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-014-9319-1

Weitere Artikel der Ausgabe 2/2015

Psychiatric Quarterly 2/2015 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.